Form 8-K - Current report:
SEC Accession No. 0001193125-24-062203
Filing Date
2024-03-07
Accepted
2024-03-07 16:19:02
Documents
15
Period of Report
2024-03-04
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d764767d8k.htm   iXBRL 8-K 26114
2 EX-10.1 d764767dex101.htm EX-10.1 14121
  Complete submission text file 0001193125-24-062203.txt   164843

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA dawn-20240304.xsd EX-101.SCH 2856
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE dawn-20240304_lab.xml EX-101.LAB 17994
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE dawn-20240304_pre.xml EX-101.PRE 11265
16 EXTRACTED XBRL INSTANCE DOCUMENT d764767d8k_htm.xml XML 3613
Mailing Address 2000 SIERRA POINT PARKWAY, SUITE 501 BRISBANE CA 94005
Business Address 2000 SIERRA POINT PARKWAY, SUITE 501 BRISBANE CA 94005 650 484-0899
Day One Biopharmaceuticals, Inc. (Filer) CIK: 0001845337 (see all company filings)

EIN.: 832415215 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40431 | Film No.: 24730398
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)